PWPei-Qiong Wu

Pei-Qiong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pei-Qiong Wu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Wen-Hui Jiang

    Department of Respiration, Guangzhou Women and Children’s Medical Center, Guangzhou, China 6

    3 shared publications
  • Chen Chen

    Department of Respirology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Gen-Quan Yin

    Department of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Liuzhou Hospital, Liuzhou, Guangxi, China, gzfezx.com

    2 shared publications
  • Aihua Lei

    Affiliations Institute of Pathogenic Biology, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, Hunan, China, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang, Hunan, China

    1 shared publication
  • Chun Chen

    Division of Hematology/Oncology, Department of Pediatrics, Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China 8

    1 shared publication
  • Chunhui He

    Department of Respiration, Guangzhou Women and Children’s Medical Center, Guangzhou, China 6

    1 shared publication

Latest Publications

  • Open Access

    Angiotensin II enhances group 2 innate lymphoid cell responses via AT1a during airway inflammation

    by Gaoyu Liu, Yingying Chen, Ying Wang, Xiaohui Deng, Qiang Xiao, Lijuan Zhang, Haixu Xu, Xu Han, Aihua Lei, Juan He, et al.

    Group 2 innate lymphoid cells (ILC2s) have emerged as critical mediators in driving allergic airway inflammation. Here, we identified angiotensin (Ang) II as a positive regulator of ILC2s. ILC2s expressed higher levels of the Ang II receptor AT1a, and colocalized with lung epithelial cells expressing angiotensinogen. Administration of Ang II significantly enhanced ILC2 responses both in vivo and in vitro, which were almost completely abrogated in AT1a-deficient mice. Deletion of AT1a or pharmacological inhibition of the Ang II–AT1 axis resulted in a remarkable remission of airway inflammation. The regulation of ILC2s by Ang II was cell intrinsic and dependent on interleukin (IL)-33, and was associated with marked changes in transcriptional profiling and up-regulation of ERK1/2 phosphorylation. Furthermore, higher levels of plasma Ang II correlated positively with the abundance of circulating ILC2s as well as disease severity in asthmatic patients. These observations reveal a critical role for Ang II in regulating ILC2 responses and airway inflammation.


  • Open Access

    Two novel mutations in TCIRG1 induced infantile malignant osteopetrosis: a case report

    by Ping Wu, Zhe Cai, Wen-Hui Jiang, Gen Lu, Pei-Qiong Wu, Zhi-Wei Xie, Jun-Zheng Peng, Chen Chen, Jun-Ye Qi, Li-Zhen Xu, et al.

    Background: Infantile malignant osteopetrosis (IMO) is a rare autosomal recessive disease characterized by a higher bone density in bone marrow caused by the dysfunction of bone resorption. Clinically, IMO can be diagnosed with medical examination, bone mineral density test and whole genome sequencing. Case presentation: We present the case of a 4-month-old male infant with abnormal skull development, hypocalcemia and premature closure of the cranial sutures. Due to the hyper bone density showed by his radiographic examination, which are characteristic patterns of IMO, we speculated that he might be an IMO patient. In order to confirm this diagnosis, a high-precision whole exome sequencing of the infant and his parents was performed. The analysis of high-precision whole exome sequencing results lead to the identification of two novel heterozygous mutations c.504-1G > C (a splicing site mutation) and c.1371delC (p.G458Afs*70, a frameshift mutation) in gene TCIRG1 derived from his parents. Therefore, we propose that there is a close association between these two mutations and the onset of IMO. Conclusions: To date, these two novel mutations in gene TCIRG1 have not been reported in the reference gene database of Chinese population. These variants have likewise not been reported outside of China in the Genome Aggregation Database (gnomAD). Our case suggests that the use of whole exome sequencing to detect these two mutations will improve the identification and early diagnosis of IMO, and more specifically, the identification of homozygous individuals with TCIRG1 gene mutation. We propose that these mutations in gene TCIRG1 could be a novel therapeutic target for the IMO in the future.


  • Open Access

    Differential proteomic analysis of children infected with respiratory syncytial virus

    by Gen-Quan Yin, Hui-Xuan Zeng, Zi-Long Li, Chen Chen, Jia-Yong Zhong, Mi-Si Xiao, Qiang Zeng, Wen-Hui Jiang, Pei-Qiong Wu, Jie-Min Zeng, et al.

    Respiratory syncytial virus (RSV) infection is the main cause of lower respiratory tract infection in children. However, there is no effective treatment for RSV infection. Here, we aimed to identify potential biomarkers to aid in the treatment of RSV infection. Children in the acute and convalescence phases of RSV infection were recruited and proteomic analysis was performed to identify differentially expressed proteins (DEPs). Subsequently, promising candidate proteins were determined by functional enrichment and protein-protein interaction network analysis, and underwent further validation by western blot both in clinical and mouse model samples. Among the 79 DEPs identified in RSV patient samples, 4 proteins (BPGM, TPI1, PRDX2, and CFL1) were confirmed to be significantly upregulated during RSV infection. Functional analysis showed that BPGM and TPI1 were mainly involved in glycolysis, indicating an association between RSV infection and the glycolysis metabolic pathway. Our findings provide insights into the proteomic profile during RSV infection and indicated that BPGM, TPI1, PRDX2, and CFL1 may be potential therapeutic biomarkers or targets for the treatment of RSV infection.